Biopharma Cred Share Price (BPCP)

Dont miss out on #CIZ GUYS CIZZLE BIOTECHNOLOGY lung cancer test trials starting in america soon! A simple blood test to diagnose lung cancer at the earliest of stages, save medical services millions per year in ct scans and mri's ;)

The market clearly didn't like it initially. Most of the fall was clawed back though.

The borrower looks likes it's struggling but doesn't follow that it we will loose money. The assets will almost certainly be sufficient.

My only worry would be the initial and probably long term effects on the share price.

What's your view.

I suspect only Pedro is going to answer but happy to hear anyone else's view?

"Decided to buy the $USD listed BPCR which has a tighter spread"

Much tighter spread, also many special dividends.

Interest rates have risen and they have captured most of it. So expect continued special dividend.

Decided to buy the $USD listed BPCR which has a tighter spread

Dated: 21 December 2022
BIOPHARMA CREDIT PLC (the 'Company') - As at the 30 November 2022 the unaudited net asset value per Ordinary Share, including current period revenue, was 100.10 cents. The Company's factsheet will be located on the Company's website, http://bpcruk.com.